Novel Adenylyl Cyclase 1 Inhibitors for Chronic Pain and Opioid Dependence

Back to all technologies
Download as PDF
2017-WATT-67991
According to a 2012 study by the American Pain Society, the annual cost of chronic pain in the United States is as high as $635 million, impacting more than 100 million people. According to the Centers for Disease Control and Prevention (CDC), 91 people die in the U.S. every day from an opioid overdose. Chronic and inflammatory pain are treated with antidepressants, anticonvulsants, and/or opioids. The use of opioids often leads to opioid dependence, which is treated with opioid substitutes such as methadone, buprenorphine, or opioid antagonists. There is a need for a treatment option for chronic and inflammatory pain that provides effective pain relief as well as eliminates opioid addiction and dependence.

Researchers at Purdue University have developed compounds that may provide an effective method of treatment for chronic and inflammatory pain by inhibiting selective adenylyl cyclases, especially adenylyl cyclase 1. These compounds may also prevent and/or reduce opioid dependence.

Advantages:
-Chronic and inflammatory pain relief
-Non-opioid
-Non-addictive
-Possibly treat opioid dependence

Potential Applications:
-Pain treatment
-Opioid dependence treatment option
Jul 18, 2018
Utility Patent
United States
(None)
(None)

Jul 18, 2017
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org